XRAY Earnings

XRAY reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 920.05M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.28 by 0%. The stock experienced a 15.5% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following XRAY's earnings announcement on 2026-02-26, the stock price moved by 15.5% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, XRAY's stock price tends to shift by an average of 6.41% in the 10 days leading up to earnings and -2.05% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate XRAY's annual revenue to reach 898.84M, while the EPS is projected at 0.39. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between XRAY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, XRAY's stock price typically moves by 6.41% in the 10 days before its earnings and -2.05% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.39 and revenue of 898.84M.

The earnings call summary presents a mixed outlook: while there are positive elements such as strategic investments, operational improvements, and a favorable agreement with Patterson, there are also concerns about declining sales and unclear management responses on key issues like free cash flow and new product launches. The Q&A section reveals optimism for future growth but also highlights uncertainties, particularly with regulatory approvals and market penetration strategies. Given the absence of a market cap, the predicted stock movement is neutral, reflecting both potential growth and existing challenges.